MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
319.76%
Quick Ratio
317.27%
Debt to Asset Ratio
43.26%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities
    • Cash and cash equivalents
    • Accounts receivable, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
204,595
102,192
183,641
112,724
Restricted cash
0
0
560
-
Marketable securities
245,095
286,540
233,627
289,113
Accounts receivable, net
96,028
100,344
85,057
72,620
Inventory
4,377
4,572
4,372
3,836
Other receivables
2,281
16,863
2,052
1,716
Prepaid expenses
9,613
26,718
13,473
21,695
Total current assets
561,989
537,229
522,782
501,704
Restricted cash, non-current
2,001
2,001
2,002
2,563
Inventory, non-current
2,525
2,528
2,532
2,532
Property and equipment, net
20,489
17,672
11,665
5,746
Intangible assets, net
6,885
7,126
7,366
7,606
Operating lease right-of-use assets
9,911
9,994
10,080
10,233
Long-term investments
6,682
3,870
3,870
3,000
Other assets
660
715
1,861
1,177
Total assets
611,142
581,135
562,158
534,561
Accounts payable
40,141
24,131
16,387
-
Accrued payroll and benefits
11,887
8,529
17,779
13,552
Other accrued liabilities
123,725
110,848
101,529
103,498
Total current liabilities
175,753
143,508
135,695
117,050
Long-term debt, net
72,762
72,597
72,438
72,281
Other long-term liabilities
15,895
16,079
10,599
10,148
Total liabilities
264,410
232,184
218,732
199,479
Common stock, 0.0001 par value 200,000,000 shares authorized 43,271,347 shares issued and outstanding at june30, 2026 (unaudited) 42,553,931 shares issued and outstanding at december31, 2025
6
6
6
6
Additional paid-in capital
799,429
782,838
769,667
753,042
Accumulated other comprehensive income (loss)
-557
-298
381
289
Accumulated deficit
-452,146
-433,595
-426,628
-418,255
Total stockholders equity
346,732
348,951
343,426
335,082
Total liabilities and stockholders equity
611,142
581,135
562,158
534,561
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$245,095K (-13.85%↓ Y/Y)Cash and cashequivalents$204,595K (111.69%↑ Y/Y)Accounts receivable, net$96,028K (64.62%↑ Y/Y)Prepaid expenses$9,613K (-67.05%↓ Y/Y)Inventory$4,377K (13.01%↑ Y/Y)Other receivables$2,281K (19.67%↑ Y/Y)Total current assets$561,989K (18.46%↑ Y/Y)Property and equipment,net$20,489K (543.90%↑ Y/Y)Operating leaseright-of-use assets$9,911K (4227.95%↑ Y/Y)Intangible assets, net$6,885K (-12.25%↓ Y/Y)Long-term investments$6,682K (122.73%↑ Y/Y)Inventory, non-current$2,525K (-0.28%↓ Y/Y)Restricted cash,non-current$2,001K (-21.93%↓ Y/Y)Other assets$660K (-45.59%↓ Y/Y)Total assets$611,142K (23.46%↑ Y/Y)Total liabilities andstockholders equity$611,142K (23.46%↑ Y/Y)Total stockholdersequity$346,732K (4.25%↑ Y/Y)Total liabilities$264,410K (62.83%↑ Y/Y)Accumulated deficit-$452,146K (-11.46%↓ Y/Y)Accumulated othercomprehensive income (loss)-$557K (-1528.21%↓ Y/Y)Additional paid-in capital$799,429K (8.29%↑ Y/Y)Total currentliabilities$175,753K (94.73%↑ Y/Y)Long-term debt, net$72,762K (0.88%↑ Y/Y)Other long-termliabilities$15,895K Common stock, 0.0001par value...$6K (0.00%↑ Y/Y)Other accruedliabilities$123,725K (57.33%↑ Y/Y)Accounts payable$40,141K Accrued payroll andbenefits$11,887K (2.37%↑ Y/Y)

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. (TARS)